Aims/hypothesis. There is little information whether cardiac capillary supply is deranged in diabetes. Hyperglycaemia is a potent stimulus for endothelin-1 (ET-1) production. We therefore hypothesised that increased ET-1 production in Streptozotocin-induced Type 1 diabetes causes abnormalities of cardiac capillaries and the aorta. To this end we compared the effects of an ET receptor A blocker (ET A -RB) with that of an ACE-inhibitor (ACE-i) or their combination in rats with Streptozotocin (STZ) diabetes. Methods. Sprague Dawley rats were injected with 65 mg STZ i.v. and subsequently developed diabetes. Rats were left untreated or received daily either the ACE-i Trandolapril, the ET A -RB Darusentan or a combination of both. After 6 months the experiment was terminated and the heart and the aorta were investigated using quantitative morphological techniques. Results. ACE-i but not ET A -RB lowered blood pressure in STZ Type 1 diabetic rats. Capillary length density was lower in untreated STZ diabetic rats (2932±128 mm/mm 3 ) compared to non-diabetic control rats (3410±252 mm/mm 3 ). Treatment with ACE-i (3568±431 mm/mm 3 ), but not with ET A -RB (2893±192 mm/mm 3 ), prevented the decrease in capillary supply. Volume density of the myocardial interstitium was higher in untreated STZ diabetic rats (0.86±0.04%) compared to non-diabetic control rats (0.36±0.06%). In all three intervention groups the values were lower (ACE-i: 0.53±0.05%, ET A -RB: 0.7±0.08% and combination: 0.69±0.1). Conclusion/interpretation. Our study identifies a capillary defect of the heart in STZ diabetes, i.e. decreased capillary supply. This abnormality was reversed by ACE-i, but not by ET A -R blockade. A similar trend, although not complete normalisation, was seen in cardiac fibrosis. [Diabetologia (2004) 47:316-324] 
Diabetes mellitus is associated with high cardiac mortality. The heart of diabetic patients has a number of abnormalities which go beyond the widely held notion of coronary heart disease from accelerated atherogenesis [1, 2] . The spectrum of structural changes in so called "diabetic cardiomyopathy" [3] comprises, amongst others, left ventricular hypertrophy, cardiac interstitial fibrosis and metabolic abnormalities. Both the renin angiotensin system (RAS) and the endothelin system (ET) are thought to play a role in the pathogenesis of cardiac fibrosis and disturbed angiogenesis. In the heart ET-1 is produced by both cardiomyocytes urine collection. Urinary albumin excretion was measured using a rat specific sandwich ELISA system as described in detail elsewhere [21] .
After 6 months the experiment was terminated by retrograde aortic perfusion with glutaraldehyde for morphometric and stereological investigations or with ice cold 0.9% NaCl for immunohistochemistry and in situ hybridisation, respectively [22] . Perfusion pressure was carefully monitored and adequacy of fixation was examined in pilot experiments.
Tissue preparation. After perfusion, the hearts of the rats were taken out to measure weight and volume. Tissue sampling and sectioning was done according to the orientator method: uniformly random sampling was achieved by preparing a set of equidistant slices of the left ventricle and the interventricular septum with a random start. Two slices were selected by area-weighted sampling and processed [22] . Eight pieces of the left ventricular wall, including the septum were embedded in Epon-Araldite. Semithin sections (1 µm) were cut, stained with methylene-blue and basic fuchsin and were examined by light microscopy with oil immersion and phase contrast at a magnification of 1000:1. After embedding, semithin sections were prepared and stained as described elsewhere [21] .
Stereological analysis
Quantitative stereology: heart. The length density (L v ) of myocardial capillaries, i.e. the length of all capillaries per unit myocardial tissue volume, and the volume density (V v ) of cardiac capillaries, defined as the volume of capillaries per unit myocardial tissue volume, were measured in eight systematically subsampled areas per section (57,600 µm 2 ) using the point-counting method and a Zeiss eyepiece with 100 points for point counting (Integrationsplatte II; Zeiss, Oberkochen, Germany) [21] . The length density of myocardial capillaries (L v ) was determined by using the equation L v =2 Q A . Q A is the area density (i.e. the number of capillary profiles per area of myocardial reference tissue) [21] .
Volume density (V v ) of interstitial tissue and myocytes was obtained using the point-counting method [21] according to the equation P p =V v . Intercapillary distance was calculated according to a modification of the formula by [23] .
Wall thickness and lumen diameter of intramyocardial arteries (diameter: 20-200 µm [24, 25] ) were determined planimetrically using a semiautomatic image analysing system (Videoplan, Kontron, Eching, Germany). Wall-to-lumen ratio was calculated by dividing wall thickness and lumen diameter as described in detail [21] .
Morphology of the aorta ascendens. Wall thickness of the aorta was measured on semithin sections using planimetry, as described in detail elsewhere [21] .
Immunohistology
Paraffin sections were prepared and were reacted with the following antibodies using the avidin biotin method: Collagen IV (α-Collagen IV, polyclonal rabbit, Bio Trend, Cologne, Germany, 1:25) and ET-A receptor (sheep ETRA, Bio Trend Köln; 1:50) were investigated. We chose the ET-A receptor, because this receptor is predominantly found in the heart of rats [26] . ET-1 and TGF-β influence each other, therefore the expression of TGF-β (TGF-β1 poyclonal rabbit, Santa Cruz, Calif., USA) was analysed.
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and endothelial cells, and cardiomyocytes express high affinity ET-1 binding sites [4, 5, 6] . ET-1 induces contraction and increases inotropy of cardiomyocytes. It also regulates salt and water homeostasis through actions on the kidney, stimulates the RAS and sympathetic nerve systems, contracts vascular smooth muscle cells and induces hypertrophy of vascular smooth muscle cells, mesangial cells and cardiomyocytes [7, 8] . ET-1 also mediates, at least in part, the chronic effects of Ang II on blood pressure [9, 10] . Conversely, ACE-inhibitors (ACE-i) and Ang II receptor type 1 blockers (AT1) diminish ET-1 expression [11, 12, 13] . In theory these findings would provide a strong rationale for the combination of endothelin receptor blockers (ET A -RB) with ACE-i or AT1 receptor blockers. ET-1 is responsible for the maintenance of basal vasomotor tone. Plasma ET-1 concentrations are increased in diabetic patients [14] and STZ-injected rats [15] . Whether increased ET-1 concentrations play a role in the genesis of structural changes of the heart has not yet been investigated. Evidence of a beneficial effect of ET on blood pressure and the heart has been provided in non-diabetic models [16, 17, 18, 19, 20] .
Our aim was to compare the effect of a specific ET-A receptor antagonist with the well documented effects of an ACE-i (as well as the combination of both) on the structural lesion of the heart in an experimental model of Type 1 diabetes, with a particular focus on capillarisation, and volume of interstitial fibrous tissue.
Methods
Animals. Male Sprague Dawley rats (Charles River, Germany, mean body weight: 176±19.8 g) were housed at constant room temperature (21°C) and humidity (75%) at a 12-h light and 12-h dark cycle. The rats had free access to water and standard rat pellets (Altromin 1324, Lage/Lippe, Germany). Experimental diabetes was induced by i.v. injection of 65 mg Streptozotocin (STZ) (Sigma Aldrich Chemie, Deisenhofen, Germany). Hyperglycaemia developed 2 days after STZ administration. Thereafter, diabetic rats were treated daily with 4.1±1.4 IU/kg body weight (bw) of long acting human insulin (Insulin Ultratard HM, Aventis, Frankfurt, Main, Germany, 40 I.U./ml). We confirm, that we followed the 'Principles of Laboratory Animal Care'.
Experimental protocol. Four days after induction of diabetes the rats were randomly allocated to the following five experimental groups: (i) untreated non-diabetic control rats (n=8), (ii) untreated diabetic rats (n=10), (iii) diabetic rats + endothelin receptor blocker (ET A -RB) (Darusentan, 50 mg/kg bw, n=9), (iv) diabetic rats + ACE-inhibitor (ACE-i) (Trandolapril, 0.3 mg/kg bw, n=12), (v) diabetic rats + ET A -RB + ACE-i in combination (with doses as above, n=12).
Medications were administered in the drinking fluid at concentrations calculated to deliver the above mentioned doses. The concentrations of drugs in the drinking fluid were adjusted accordingly. Daily food and water consumption were monitored. Body weight, blood glucose and blood pressure (by tail plethysmography) were measured at regular intervals. After 3, 5 and 6 months the rats were kept in metabolic cages for a 24-h Cryostat sections that were 5 µm thick were prepared and were reacted with the following antibodies using the avidin biotin method [10] : Collagen I (α-Collagen I, polyclonal rabbit, Chemicon, Tenecula, Calif., USA, 1:2000) and ET-1 (α-ET-1 polyclonal rabbit, Biotrend, Cologne, Germany, 1:50). The concentration that was optimal for staining was evaluated testing different dilution series in a pilot study. Two investigators who were blinded with regard to the animal group did semiquantitative scoring as described in detail [22] . . After incubation at 42°C for 45 min, the enzyme was denatured for 5 min at 94°C. Semiquantification of ET-1 and TGF-β mRNA was carried out using deletion mutants of the ET-1 and TGF-β cDNA as internal standard. The amplifications of the mutants resulted in PCR products of 300 bp for ET-1 and 302 bp for the TGF-β. The mutant cDNAs were added to the PCR mixture. Endogenous ET-1 0.4 pg or TGF-β 0.05 pg of plasmid respectively was added to the PCR mixture per sample. The PCR products were separated in a 3% metaphorgel and scanned as TIF data. The quotient of measured endogenous sample and aquivalent mutant was calculated by Scion-Image-program (National Institutes of Health, Bethesda, Md., USA).
In situ hybridisation for localisation of cardiac ET-1 and TGF-β mRNA expression Because plasma ET-1 concentrations are increased in diabetes and antagonism of the ET system might be effective, mRNA expression of ET-1 was measured. ET-1 and TGF-β influence each other, subsequently mRNA expression of TGF-β was measured also. For in situ hybridisation, transversal cryostat section of the myocardium (10 µm) were used. Probe preparation, labelling, hybridisation and development were carried out as described in detail elsewhere [22] .
Statistics
All data are expressed as means ± SD. Kruskal-Wallis test and ANOVA, respectively, were chosen for analysis of variance, followed by the least-significant difference test to assess the differences between the groups. Results were considered significant if the p value was less than 0.05.
Results
Animal data. Untreated diabetic rats had stable, moderate hyperglycaemia throughout the 6 months of the study with a mean blood glucose concentration of 36.1±5.8 mmol/l and a mean HbA 1c of 9.7±0.5%. Blood glucose concentrations were not modified by either ACE-i or ET A -RB treatment. Despite higher food intake (58±6 g/day) in diabetic compared to nondiabetic rats (37±3 g/day), body weight was lower in untreated diabetic rats. Body weight, as well as food or water intake were not modified by treatment with ACE-i or ET A -RB or both combined ( Table 1) .
The relative weight of the left ventricle, i.e. left ventricular weight/body weight ratio, was higher in all diabetic groups compared to non-diabetic rats (p<0.05). It was lower (p<0.05), but not normalised, when diabetic rats were treated with the ET A -RB and the ACE-i. Serum cholesterol and LDL cholesterol concentrations were not significantly (p<0.05) different between the experimental groups. Serum triglyceride concentrations were significantly higher in untreated diabetic rats (4.2±0.17 mmol/l) than in non-diabetic controls (1.06±0.35 mmol/l ) and in treated diabetic rats (2.5±1.65 mmol/l ET A -RB, 1.8±1.12 mmol/l ACE-i and 1.4±0.7 mmol/l combination).
After 6 months of diabetes, systolic blood pressure (bp) was higher in untreated diabetic rats compared to non-diabetic control rats; it was lower in rats treated with ACE-i and with the combination. In diabetic rats treated with the ET A -RB bp ranged between untreated and ACE-i treated diabetic rats, but was still significantly (p<0.05) lower than in untreated diabetic control rats. Urinary albumin excretion as an index of renal dysfunction was higher in untreated diabetic than in nondiabetic rats (p<0.05). Urinary albumin excretion was reduced and nearly normalised by ACE-i and combination treatment, but not by ET A -RB treatment.
Quantitiative morphology of the myocardium (Fig. 1) . Capillary length density was lower and mean intercapillary distance higher in untreated diabetic compared to non-diabetic control rats. Only ACE-i administered as mono therapy or in combination, but not ET A -RB, prevented the abnormality of myocardial capillary supply in diabetes ( Table 2 , Fig. 1) .
The volume density of the interstitial tissue was increased in untreated diabetic compared to control rats and treated diabetic rats indicating cardiac fibrosis. Again, the treatment with the ACE-i was associated with the most marked prevention of the increase in interstitial tissue.
Quantitiative morphology of intramyocardial arterioles and of the aorta. The lumen diameter of intramyocardial arterioles was increased in untreated diabetic rats compared to non-diabetic control rats (p<0.05). Only ACE-i treatment alone or in combination prevented such arteriolar enlargement, but not ET A -RB. Wall thickness of intramyocardial arterioles was increased in diabetic compared to control rats. It was lower in all intervention groups, but ACE-i in mono therapy or in combination, was more effective than ET A -RB. This was also true for the changes in walllumen ratio which went in parallel ( Table 3) .
The wall thickness of the aorta was increased in untreated diabetic rats compared to non-diabetic control rats and all treated diabetic rats (p<0.05). The lumen diameter of the aorta was decreased in diabetic rats compared to control rats. Intervention with ACE-i mono therapy only significantly (p<0.05) improved data. ET-A receptor protein expression by semiquantitative scoring was higher (p<0.05) in capillary endothelial cells and myocytes of untreated diabetic rats (2.0±0.3) compared to non-diabetic control rats (0.5±0.3). In diabetic rats ET-A receptor expression was lower (p<0.05) after ACE-i (1.4±0.3) or combination treatment (1.3±0.3), but not ET A -RB treatment (1.8±0.4).
TGF-β protein expression was significantly higher (p<0.05) in untreated diabetic (1.3±0.4) and ET A -RB (1.3±0.3) treated rats compared to decreased expression in non-diabetic control (0.5±0.3), ACE-i treated (0.5±0.3) and combination treated diabetic rats (0.6±0.1).
Collagen IV protein expression was higher (p<0.05) in untreated diabetic (1.01±0.5) compared to non-diabetic rats (0.07±0.01). All interventions reduced expression for collagen IV, but ACE-i and combination treatment were more effective (diabetes + ET A -RB: 0.43±0.06; diabetes + ACE-i: 0.25±0.14; diabetes + combination: 0.19±0.01).
Collagen I protein expression was not significantly (p<0.05) different between experimental groups.
Semiquantitative RT-PCR for cardiac ET-1 and TGF-β mRNA expression.
Relative ET-1 mRNA expression was increased (p<0.05) in the heart of untreated diabetes compared to non-diabetic control rats. Cardiac ET-1 mRNA expression was lower (p<0.05) in diabetic rats on combination treatment, but not in ACE-i and ET A -RB treated diabetic rats (Fig. 2) .
In parallel, cardiac TGF-β mRNA was higher (p<0.05) in untreated diabetic rats compared to nondiabetic control rats. All interventions led to statistically significant lower TGF-β mRNA levels, but they were normalised only in the combination group. Data are given as mean ± SD a p<0.05 vs non-diabetic control, b p<0.05 vs untreated diabetes, c p<0.05 ET A -RB treated diabetic rats vs ACE-i treated ment with ACE-i nor with ET A -RB or the combination lowered ET-1 gene expression. TGF-β mRNA expression of interstitial cells was increased (p<0.05) in diabetic rats. All interventions lowered the expression.
Discussion
Our study identifies decreased capillary supply as well as increased mean intercapillary distance as a new finding and confirmed marked interstitial fibrosis in the heart in experimental Type 1 STZ-induced diabetes. As to the pathomechanisms involved, it is of interest that the expression of collagen IV, ET-1 and TGF-β was increased in untreated STZ diabetic rats. Treatment with an ACE-i, but not with ET A -RB, abrogated both the capillary abnormality and the interstitial fibrosis. Combination of ACE-i and ET A -RB had no additive beneficial effect. In situ hybridisation (Fig. 3) . ET-1 mRNA expression of interstitial and capillary endothelial cells (Fig. 3) was increased (p<0.05) in the heart of untreated diabetic rats compared to non-diabetic control rats. Neither treat-
The finding of diminished capillary-length density reflects the failure of the capillary growth and the failure to increase pari passu with the increase of cardiomyocyte volume, creating capillary/cardiomyocyte mismatch. The increased mean intercapillary distance implies that the distance from the centre of the capillaries to the centre of the cardiomyocyte, and by implication for oxygen diffusion, is increased. Although the study does not provide direct evidence, it seems logical that diminished capillary supply is at least one major cause contributing to the impaired ischaemia tolerance of the heart in diabetes.
We also confirmed previous findings of interstitial fibrosis i.e. non-replacement type of fibrosis. In the replacement type of fibrosis, fibrous tissue substitutes for vanished necrotic parenchyma. In contrast, the type of fibrosis we documented in the STZ diabetic heart constitutes primary fibrosis resulting from activation of interstitial fibroblasts, similar to what has been documented in rats exposed to aldosterone [27] or Ang II [28] . Cardiac fibrosis impairs left ventricular compliance, causes an abnormal stress relationship and (particularly in conjunction with diminished blood supply) interferes with the electrical stability of the heart [29] .
As to the pathomechanisms involved, we found increased expression of ET-1, ET receptor, TGF-β and collagen IV in untreated STZ diabetic rats, confirming, at least in part, data of other laboratories [30, 31, 32] . A further finding of potential pathogenetic relevance was increased systolic blood pressure measured by tail plethysmography.
The influence of ET A -RB on bp is controversial, but several confounders make the comparison of the reported data difficult e.g. different administered doses, differences in animal models used and differences in bp measurement techniques [33, 34, 35] . Of note, ET A -RB lowered bp in diabetic rats in our study. The maximal decrease in bp was seen with combination treatment. The increase in systolic bp in diabetes mellitus could be related to the stimulatory effect of hyperglycaemia on the RAS [36, 37, 38] or generation of oxygen radical species reducing the availability of nitric oxide [39] . A normalisation of systemic bp in nonselective ET-1 blockade in diabetic rats is described [40] . At the same dose of Darusentan, no bp lowering was noted in rats with surgical ablation of the kidney [19, 41] further suggesting that the role of ET is specific for diabetes. A small but sustained reduction of 24-h blood pressure with Darusentan was noted, whereas endothelin-dependent vasorelaxation remained unchanged [42] .
Using a two dimensional approach a significant increase of cardiac capillaries in STZ rats after ET A -RB treatment is noted [33] . This finding is in contrast to our results using a stereological technique permitting analysis in three dimensional space. The above results using conventional methodology could easily have been flawed, however, by the anisotropy of cardiac tissue.
The ET receptor antagonist abrogated dysfunction of cultured endothelial cells exposed to high glucose concentrations [43] . It also has been shown that ET-1 mRNA receptor binding is increased in the hearts of diabetic rats [5, 44] , similar to what is found in cardiac disease [13] . In the present long-term study increased ET-1 and ETA receptor expression could also be demonstrated in diabetic rats. ET-1 expression was decreased only by combination therapy. In contrast, increased expression of ET-A receptor was also reduced by ACE-i (and combination) therapy, but not by ET A -RB. This observation suggests a major role of the RAS in the up-regulation of the ET system in the heart of diabetic rats. Data reported in the literature are consistent with a high vascular ACE activity, which could be an important factor for the progressive deterioration of vascular function in STZ rats [45] .
It is not clear why the ET A -RB was less effective to prevent capillary deficit in the heart, although the ET-1 system is up-regulated in diabetes. One explanation proposed by some authors is that damaged cardiomyocytes are unable to synthesise ET-1 in response to Ang II stimulation [13, 39, 46] . For diabetes this explanation is excluded by our results. We cannot exclude, however, post receptor abnormalities in diabetes, so that ETA receptor stimulation fails to yield an appropriate response. It has been speculated that an activated local RAS is responsible for an increased AT 2 receptor mediated response to ANG II in cardiomyocytes and subsequent apoptosis [46] . This hypothesis could explain the superior efficacy of the ACE-i in our study. Interestingly, in diabetes apoptosis of cardiomyocytes seem to occur independent of hypertension [39] .
We found that ET A -RB lowered cardiac interstitial fibrosis and wall thickness of the aorta. The volume density of the interstitium was lower in all intervention groups. ACE-i, but not ET A -RB prevented the increase in wall thickness of intramyocardial arteries. However, the wall-to-lumen ratio of intramyocaradial arteries was also reduced by ET A -RB compared to non-diabetic rats. The increase in aortic wall thickness was prevented by ET A -RB and ACE-i suggesting a role for endogenous ET in the pathogenesis of vessel disease in diabetes. Additionally, ET A -RB prevented bp increase and vascular remodelling in large and small vessels in a model of salt-sensitive hypertension [47] .
The relationship between ET-1 and TGF-β is complex: ET-1 stimulates TGF-β synthesis [48] , and in turn TGF-β augments ET-1 expression as part of a positive feedback cycle [49] . In contrast to results of others [50] , in our study ET A -RB reduced TGF-β mRNA expression as potently as the ACE-i. The combination of the two interventions provided no further benefit. Diabetes was associated with increased TGF-β mRNA expression. Such overexpression was reduced by ET A -RB and by ACE-i. This finding confirms that ET-1 increases TGF-β, at least in this model, and this could be one mechanism causing the increase in interstitial tissue and arterial wall thickness. On the other hand ET-1 mRNA was increased in diabetic rats and this increase was only prevented by combination treatment.
The modification of extracellular matrix components by advanced glycation leads to increased collagen cross linking and increased myocardial stiffness in diabetes [31] . In addition our study showed increased expression for collagen IV in diabetic rats. All interventions reduced its expression, but ACE-i and combination treatment were more effective than the ET A -RB.
In conclusion, this study identifies a myocardial capillary deficit in diabetes. Furthermore, treatment with ACE-i was more effective than blockade of the ET-system in preventing interstitial fibrosis and capillary defect of the heart in diabetic rats. This observation documents a major pathophysiological role of the RAS in the pathogenesis of the cardiac abnormality, but the ET system seems to play a certain role in the genesis of diabetic vessel disease.
